Instrument Inactif

Autres langues ISIS Pharmaceuticals, Inc. Nasdaq

Actions

US4643301090

Recherche biotechnologique et médicale

Autres langues

04/09	Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- 2nd Update
04/09	Novartis, Ionis' experimental heart drug misses key goal in closely watched trial
04/09	Stocks to Watch : Ionis Pharmaceuticals, Novartis, Corvex
04/09	Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- Update
04/09	Ionis-Novartis heart drug misses main goal of late-stage trial
04/09	Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
04/09	Ionis Pharmaceuticals Reports Topline Results for Pelacarsen in Lp(A)Horizon Phase 3 Study
04/09	Ionis Pharmaceuticals' Zanvastro Approval Sets Path for Independent Neurology Business, Oppenheimer Says
04/09	Ionis Pharmaceuticals - ZANVASTRO approved by the FDA as the first and only disease modifying treatment for Alexander disease in pediatric and adult patients
04/09	Ionis Pharmaceuticals Gets FDA Approval for Alexander Disease Treatment
04/09	Ionis Pharmaceuticals Announces FDA Approval Of Zanvastro For Treatment Of Alexander Disease In Pediatric And Adult Patients
04/09	ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
03/09	Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose
03/09	US FDA approves Ionis Pharma's therapy to treat rare genetic disorder
03/09	Ionis to present at upcoming investor conferences
03/09	Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
31/08	Trump administration to announce drug pricing deals
20/08	Ionis Pharmaceuticals Presents New Data In The Management Of Severe Hypertriglyceridemia At The European Society Of Cardiology Congress 2026
20/08	Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
31/07	Ionis Pharmaceuticals Insider Bought Shares Worth $1,058,700, According to a Recent SEC Filing
29/07	Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
29/07	Ionis Pharmaceuticals, Inc. Announces Retirement of Frank Bennett from Executive Vice President and Chief Scientific Officer Roles, Effective February 2027
29/07	Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year of 2026
29/07	Earnings Flash (IONS) Ionis Pharmaceuticals, Inc. Reports Q2 Revenue $268.0M, vs. FactSet Est of $189.1M
29/07	Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q2 Loss $0.69 a Share, vs. FactSet Est of $1.08 Loss